Organic anion transporting peptide-based cancer imaging and therapy

Abstract

Dye-drug conjugates and methods for diagnosing, detecting, or treating cancer wherein the dye-drug conjugates are selected from the following structures:

What is claimed is: 
     
         1 . A dye-drug conjugate selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The dye-drug conjugate of  claim 1  which has the following structure: 
       
         
           
           
               
               
           
         
       
     
     
         3 . The dye-drug conjugate of  claim 1  which has the following structure: 
       
         
           
           
               
               
           
         
       
     
     
         4 . A dye-drug conjugate provided with a vehicle suitable for administration to a patient, wherein the dye-drug conjugate is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
     
     
         5 . The dye-drug conjugate provided with vehicle according to  claim 4 , wherein the dye-drug conjugate has the following structure: 
       
         
           
           
               
               
           
         
       
     
     
         6 . The dye-drug conjugate provided with vehicle according to  claim 4 , wherein the dye-drug conjugate has the following structure: 
       
         
           
           
               
               
           
         
       
     
     
         7 . A method for diagnosing, detecting or treating cancer, comprising the step of administering to a subject suffering or suspected to suffer from cancer, or to a sample of the subject, an effective amount of a dye-drug conjugate, and optionally imaging the subject or a sample of the subject, wherein the dye-drug conjugate is selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         8 . The method of  claim 7 , wherein the dye-drug conjugate has the following structure: 
       
         
           
           
               
               
           
         
       
     
     
         9 . The method of  claim 7 , wherein the dye-drug conjugate has the following structure: 
       
         
           
           
               
               
           
         
       
     
     
         10 . The method of  claim 8 , wherein the cancer is one selected from the group consisting of prostate cancer, breast cancer, renal cancer, pancreatic cancer, lung cancer, and hepatic cancer. 
     
     
         11 . The method of  claim 9 , wherein the cancer is one selected from the group consisting of prostate cancer, breast cancer, renal cancer, pancreatic cancer, lung cancer, and hepatic cancer. 
     
     
         12 . The method of  claim 8  for treating cancer, comprising the step of administering to a subject suffering or suspected to suffer from cancer an effective amount of the dye-drug conjugate, and optionally imaging the subject or a sample of the subject. 
     
     
         13 . The method of  claim 9  for treating cancer, comprising the step of administering to a subject suffering or suspected to suffer from cancer an effective amount of the dye-drug conjugate, and optionally imaging the subject or a sample of the subject. 
     
     
         14 . The method of  claim 8  for diagnosing or detecting cancer, comprising the step of administering to a subject suffering or suspected to suffer from cancer, or to a sample of the subject, an effective amount of a dye-drug conjugate, and imaging the subject or a sample of the subject. 
     
     
         15 . The method of  claim 9  for diagnosing or detecting cancer, comprising the step of administering to a subject suffering or suspected to suffer from cancer, or to a sample of the subject, an effective amount of a dye-drug conjugate, and imaging the subject or a sample of the subject. 
     
     
         16 . The method of  claim 12 , wherein the cancer is one selected from the group consisting of prostate cancer, breast cancer, renal cancer, pancreatic cancer, lung cancer, brain tumor, and hepatic cancer. 
     
     
         17 . The method of  claim 13 , wherein the cancer is one selected from the group consisting of prostate cancer, breast cancer, renal cancer, pancreatic cancer, lung cancer, brain tumor, and hepatic cancer. 
     
     
         18 . The method of  claim 14 , wherein the cancer is one selected from the group consisting of prostate cancer, breast cancer, renal cancer, pancreatic cancer, lung cancer, brain tumor, and hepatic cancer. 
     
     
         19 . The method of  claim 15 , wherein the cancer is one selected from the group consisting of prostate cancer, breast cancer, renal cancer, pancreatic cancer, lung cancer, brain tumor, and hepatic cancer.